# A Study Comparing 4 Dose Regimens of PLA-695, Naproxen, and Placebo In Subjects With Osteoarthritis Of The Knee

> **NCT00396955** · PHASE2 · TERMINATED · sponsor: **Wyeth is now a wholly owned subsidiary of Pfizer** · enrollment: 560 (—)

## Conditions studied

- Osteoarthritis

## Interventions

- **DRUG:** PLA-695

## Key facts

- **NCT ID:** NCT00396955
- **Lead sponsor:** Wyeth is now a wholly owned subsidiary of Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2006-11
- **Primary completion:** 2007-11
- **Final completion:** 2007-11
- **Target enrollment:** 560 (—)
- **Why stopped:** imbalance of gastrointestinal and the lipase events
- **Last updated:** 2007-12-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00396955

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00396955, "A Study Comparing 4 Dose Regimens of PLA-695, Naproxen, and Placebo In Subjects With Osteoarthritis Of The Knee". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT00396955. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*